On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...

A year after missing on a trial endpoint, Travere Therapeutics can breathe a sigh a relief. | A year after missing on a trial ...

London: The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease ... The FDA's latest approval ...

Travere Therapeutics TVTX announced that the FDA granted full approval to its oral non-immunosuppressive drug Filspari ...

Novartis’ Fabhalta (iptacopan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to reduce excess protein in the urine (proteinuria) of patients with the rare kidney ...

The company had focused its resources on Filspari’s launch in IgAN after the US FDA snubbed the therapy in another rare ...

The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...

the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A ...